The European League Against Rheumatism (EULAR) recommends that the treatment of RA, updated in 2019, include TNF-α and IL-6 inhibitors as biological disease-modifying antirheumatic drugs (bDMARDs) for patients with poor prognostic factors and insufficient control with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). This evidence concerns the gene TNF and rheumatoid arthritis.